山河药辅：股东复星医药计划减持不超过约698万股

Group 1 - Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. plans to reduce its stake in Shanhe Pharmaceutical Excipients Co., Ltd. by up to approximately 6.98 million shares, which is no more than 3% of the total share capital after deducting repurchased shares [1] - The reduction will occur within 90 days after a 15 trading day period following the announcement [1] - Shanhe Pharmaceutical Excipients' revenue composition for the year 2024 is expected to be 100% from the pharmaceutical manufacturing industry [1] Group 2 - As of the report, Shanhe Pharmaceutical Excipients has a market capitalization of 3.3 billion yuan [2]